Evidence map›Paper›PMID 36145332›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro.

Inés Roger, Paula Montero, Antonio García, Javier Milara, Pilar Ribera, Jose Alejandro Pérez-Fidalgo, Julio Cortijo

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Inés RogerBiomedical Research Networking Centre on Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain.
Paula MonteroDepartment of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-5929-5486
Antonio GarcíaDepartment of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0003-2939-9265
Javier MilaraBiomedical Research Networking Centre on Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain.
Pilar RiberaDepartment of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain.
Jose Alejandro Pérez-FidalgoDepartment of Medical Oncology, University Clinic Hospital of Valencia, 46010 Valencia, Spain.
Julio CortijoBiomedical Research Networking Centre on Respiratory Diseases (CIBERES), Health Institute Carlos III, 28029 Madrid, Spain.
Universitat de València · ESHospital Clínico Universitario de Valencia · ES

Funding

CIBERES, Spanish Government CB06/06/0027European Regional Development Fund (FEDER), and Instituto de Salud Carlos III PID2020-114871RB-I00Generalitat Valenciana 2017/023/UVInstituto de Salud Carlos III PI20/01363
6 · The paper itself

Abstract

Delayed-type hypersensitivity (DTH) is caused by a broad number of drugs used in clinic, and antineoplastic drugs show an elevated proportion of DTH, which potentially affects the quality of life of patients. Despite the serious problem and the negative economic impact deriving from market withdrawal of such drugs and high hospitalization costs, nowadays, there are no standard validated methods in vitro or in vivo to evaluate the sensitizing potential of drugs in the preclinical phase. Enhanced predictions in preclinical safety evaluations are really important, and for that reason, the aim of our work is to adapt in vitro DPRA, ARE-Nrf2 luciferase KeratinoSens

Indexed as

antineoplasticdelayed-type hypersensitivity (DTH)DPRAhCLATKeratinoSensTM

Identifiers

PMID36145332
PMCPMC9501359
OpenAlexW4296808852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.